Health Care·Biotechnology·$185.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $3.69 | N/A | +4.19% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $3.69 | N/A | +4.19% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management expressed confidence in the company's strategic direction. They emphasized the importance of innovation and market presence.
Management highlighted strong performance in key therapeutic areas.
They noted ongoing investments in R&D to drive future growth.
Amgen's earnings report showed a positive surprise on EPS, which contributed to a slight increase in the stock price. The management's focus on R&D and strong performance in key areas indicates a commitment to future growth. However, the lack of revenue data and guidance leaves some uncertainty for investors.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
WASTE CONNECTIONS IN
Oct 29, 2018